AbbVie is firing its heart drug sales force as patent protection expires on its leading heart drugs, leading to more competition from generic medications. More
-
Sponsored By:
-
Sponsored By:
-
Sponsored By:
ABBV
Recent Articles
Abbott Labs and Abbvie: Should Dividend Investors Hold?
Now that Abbott Laboratories has split into Abbott and AbbVie, here's a look at each of the new parts, and what dividend investors should look for. More
Spinoff Mania Is Winding Down (And Good Riddance!)
Sooner rather than later, investors will wake up to the reality of the spinoff boom: These deals aren't all "unlocking value." More
